The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Acton, Massachusetts-based Insulet’s Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January. That clearance covered individuals six years of age and older.

In June, the company presented data supporting the use of Omnipod 5 in young children, with the platform significantly improving time in range and reducing HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance Tagged With: FDA, Insulet

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.